| CAS NO: | 900814-48-4 |
| 包装 | 价格(元) |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 900814-48-4 |
| 别名 | N-[2-[[(1S)-2'-(3-甲基丁氧基)[1,1'-联萘]-2-基]氧基]乙酰基]-D-赖氨酰-D-精氨酰-L-亮氨酸3-甲基丁基酯盐酸盐 |
| Canonical SMILES | O=C(NC(CCCCN)C(NC(CCCNC(N)=N)C(NC(CC(C)C)C(OCCC(C)C)=O)=O)=O)COC1=C(C(C(C=CC=C2)=C2C=C3)=C3OCCC(C)C)C(C=CC=C4)=C4C=C1.Cl.Cl |
| 分子式 | C50H73Cl2N7O7 |
| 分子量 | 955.06 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | AVX 13616 shows the potent in vivo antibacterial activity of Avexa's lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens.IC50 value: 2-4 ug/ml (MICs)Target: antibacterial agent AVX13616 was as active as mupirocin in a nasal decolonization model but required only a single application. The compounds are being developed for topical indications and/or wound infection/catheter-related infections. AVX13616 and other compounds showed broad spectrum antibacterial activity against a range of isolates with MICs of 2-4 micrograms per millilitre against S. aureus, coagulase negative staphylococci, enterococci, MRSA, VISA and VRSA. A single application of 5% (w/w) AVX13616 (approximately equimolar to 2% mupirocin) was as effective as 2% mupirocin administered twice a day for five days in nasal decolonisation of MRSA in mice. [1]. Avexa Presents Data from Apricitabine and Antibacterial Programs at two International Conferences |
m.cnreagent.com